About GlycosBio
GlycosBio is a Healthcare company based in Houston (United States) founded in 2007 by Richard Cilento. Industrial biotechnology company focusing on development of specialty chemicals and food supplements. GlycosBio has raised $16.78 million across 8 funding rounds from investors including DFJ, EIV Capital and Mercury Fund. The company has 7 employees. GlycosBio offers products and services including Activated Oil Systems and Bioavailability Research. Its focus areas include Life Sciences, Nutraceuticals Tech, Dietary Supplements and Disease Specific. Its legal entity is GLYCOS BIOTECHNOLOGIES INC. Its competitors include ChromaDex, LifeVantage and Bloom Nutrition; 1 of its 3 listed competitors has raised funding.
Company details
GlycosBio is a scientifically focused biotechnology company with expertise in molecular biology as well as metabolic engineering. The company leverages metabolic engineering and associated process development for the production of specialty chemicals like Lactic Acid and Isoprene from crude glycerol, palm fatty acid distillates, and glucose for the preparation of food additives, biodegradable plastics, etc. GlycosBios nutraceuticals platform also supports the production of food ingredients like Non-GMO enriched proteins, dietary fiber, concentrated omega-3 fatty acids and probiotics from rice bran, fish and algal oil, and palm kernel cake.
- Headquarters Houston, United States
- Employees 7
- Founders Richard Cilento
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website glycosbio.com
- Social LinkedIn
- Legal Name Glycos Biotechnologies Inc
- Total Equity Funding$16.78M (USD)
in 8 rounds
- Latest Funding Round$1.13M (USD), Series C
Mar 2024
- InvestorsDFJ
& 2 more
- Employee Count7
Products & Services of GlycosBio
GlycosBio offers a comprehensive portfolio of products and services, including Activated Oil Systems and Bioavailability Research.
Enhances therapeutic benefits of natural materials via lipid engineering.
Improves nutrient absorption for patients with gastrointestinal issues.
Funding Insights of GlycosBio
GlycosBio has successfully raised a total of $16.78M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $1.13 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.78M
- Total Rounds 8
- Last Round Series C — $1.13M
- First Round $1.81M
(Feb 2008)
- Investors Count 3
All 8 funding rounds of GlycosBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $1.13M | Series C | – | – | – |
| Apr 2023 | $425,000 | Series B | – | – | – |
| Dec 2016 | $829,846 | Series B | – | – | – |
| Oct 2013 | $375,250 | Series A | – | – | – |
| Feb 2013 | $3M | Series A | – | DFJ | – |
| Oct 2010 | $4.22M | Series A | – | EIV Capital | – |
| Mar 2009 | $5M | Series A | – | DFJ, Mercury Fund | – |
| Feb 2008 | $1.81M | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in GlycosBio
GlycosBio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include DFJ, EIV Capital and Mercury Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US focused VC firm | dfj.com | Menlo Park, United States | ||
Growth equity is invested in sustainable energy businesses by EIV Capital. | eivcapital.com | Houston, United States | ||
Early-stage investments are directed toward US, India, and Canada firms. | mercuryfund.com | Houston, United States |
Investor details for GlycosBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GlycosBio
3 people are tracked at GlycosBio (3 in leadership); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Richard Cilento | Co-Founder | Leadership |
Kevin Mitchell | VP-Finance | Leadership |
Chad Conger | Chief Strategy And Commercial Officer | Leadership |
Complete people profiles for GlycosBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GlycosBio
3 dated milestones of GlycosBio across 17 years, from founding to its latest funding, stage changes and deals.
- Founded GlycosBio is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Series C, of $1.1M.
Competitors of GlycosBio
GlycosBio has 3 listed competitors in our database, 1 of them funded. They include ChromaDex, LifeVantage and Bloom Nutrition.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| chromadex.com | 1999 | Irvine, United States | $3.35M | 228 | Nutritional ingredients for health and wellness are developed. | |
| lifevantage.com | 2003 | Monroe, United States | 248 | Nutritional products for various health ailments are provided. | ||
| bloomnu.com | 2019 | Venice, United States | 41 | Health and wellness nutritional supplements are provided by Bloom Nutrition. |
Detailed competitors of GlycosBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Nutraceutical & Food-as-Medicine Platforms
3 companies that operate in the same segment as GlycosBio (Nutraceutical & Food-as-Medicine Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapies for metabolic health in chronic disease patients are provided. | 2014 | San Francisco, California, United States | USD 401.78 M | 910 | ||
Personalized gut health solutions are provided by ZOE. | 2017 | New Castle, Pennsylvania, United States | USD 15 M | |||
Machine learning-based bioinformatics solutions for health insights are provided. | 2016 | Los Alamos, New Mexico, United States | USD 301.57 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glycosbio
Complete news archive for GlycosBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GlycosBio
GlycosBio was founded in 2007 and raised its 1st funding round 1 year after it was founded.
GlycosBio is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
GlycosBio is a funded company, having raised a total of $16.78M across 8 funding rounds to date. The company's 1st funding round was a Seed of $1.81M, raised on Feb 2008.
GlycosBio has 7 employees.
GlycosBio is a scientifically focused biotechnology company with expertise in molecular biology as well as metabolic engineering. The company leverages metabolic engineering and associated process development for the production of specialty chemicals like Lactic Acid and Isoprene from crude glycerol, palm fatty acid distillates, and glucose for the preparation of food additives, biodegradable plastics, etc. GlycosBios nutraceuticals platform also supports the production of food ingredients like Non-GMO enriched proteins, dietary fiber, concentrated omega-3 fatty acids and probiotics from rice bran, fish and algal oil, and palm kernel cake.
GlycosBio's top competitors include ChromaDex, LifeVantage and Bloom Nutrition.
GlycosBio offers Activated Oil Systems and Bioavailability Research.
GlycosBio has 3 investors. Key investors include DFJ, EIV Capital, and Mercury Fund.
GlycosBio operates through Glycos Biotechnologies Inc.